H.C. Wainwright raised the firm’s price target on Structure Therapeutics (GPCR) to $80 from $75 and keeps a Buy rating on the shares. The firm says aleniglipron exhibits “structural uniqueness, with slightly distinct properties that could drive differentiated weight-loss outcomes in the ACCESS trials.” It views the orforglipron and danuglipron data as encouraging for aleniglipron.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating
- Buy Rating for Structure Therapeutics: Promising Phase 2b Results and Strategic Market Positioning
- Promising Developments in Weight Management Propel Buy Rating for Structure Therapeutics
- Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs
- Apple downgraded, Reddit upgraded: Wall Street’s top analyst calls